A5055511100- Head and Neck Cancer Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- RNA Interference and Gene Delivery
- Xenotransplantation and immune response
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Urinary and Genital Oncology Studies
- Urinary Bladder and Prostate Research
- Tryptophan and brain disorders
- Inflammatory Biomarkers in Disease Prognosis
- Ferroptosis and cancer prognosis
- Neonatal Respiratory Health Research
- Immune cells in cancer
- Urologic and reproductive health conditions
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
Purdue University West Lafayette
2011-2024
University of North Carolina at Chapel Hill
2017-2024
University of North Carolina Health Care
2022-2023
Purdue University Institute for Cancer Research
2023
UNC Lineberger Comprehensive Cancer Center
2020
Georgetown-Howard Universities Center for Clinical and Translational Science
2017
Baylor College of Medicine
2017
Center for Cancer Research
2015
Genomics Research Center, Academia Sinica
2009
Heterogeneity of cancer stem/progenitor cells that give rise to different forms has been well demonstrated for leukemia. However, this fundamental concept yet be established solid tumors including breast cancer. In communication, we analyzed tumor stem cell markers in human lines and primary specimens using flow cytometry. The properties marker expressing-cell populations were further assessed by vitro soft agar colony formation assay the ability form NOD/SCID mice. We found expression...
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (<pT2) the neoadjuvant setting. In LCCC1520 (NCT02690558), a phase 2 single-arm trial chemo-immunotherapy (gemcitabine cisplatin plus pembrolizumab; NAC-ICI) MIBC, 22/39 patients responded (pathologic downstaging as primary outcome), previously described....
Abstract Purpose: Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), contraindication common. Radiation elicits promotes tumor-directed immune stimulation, which may potentiate anti–PD-1 therapy. We provide the first efficacy report combined pembrolizumab definitive in LA-HNSCC. Patients Methods: This single-arm, multi-institution, phase II study (NCT02609503) enrolled 29 cisplatin-ineligible patients. received...
Blockade of immune checkpoint proteins (e.g., CTLA-4, PD-1) improves overall survival in advanced melanoma; however, therapeutic benefit is limited to only a subset patients. Because blockade acts by "removing the brakes" on effector T cells, efficacy may be constrained pool melanoma-reactive cells periphery. In thymus, autoimmune regulator (Aire) promotes deletion reactive against self-antigens that are also expressed tumors. Thus, while protecting autoimmunity, Aire limits generation...
Abstract BACKGROUND Prostatitis is a poorly understood disease and increasing evidence suggests inflammation involved in other prostatic diseases including prostate cancer. METHODS The ability of pre‐activated CD8 T cells to induce prostatitis was examined by adoptive transfer antigen specific into POET‐3 mice or POET‐3/Luc/ Pten −/+ mice. Characterization the inflammatory response determined examining leukocyte infiltration histological analysis, flow cytometry evaluating cytokine chemokine...
BACKGROUND The presence of inflammation in prostate cancer (PCa) and benign hyperplasia (BPH) has been well described but the cellular mechanisms by which modulates are currently unclear. Prostate stem cells (PSC) not only maintain homeostasis also considered to be cell origin PCa an important contributor BPH. However, impact on PSC is understood. Therefore, we initiated studies evaluate effect PSC. METHOD Ovalbumin specific CD8+ T were intravenously delivered intact castrated ovalbumin...
Chronic prostate inflammation in patients with benign hyperplasia (BPH) correlates the severity of symptoms. How contributes to enlargement and/or BPH symptoms and underlying mechanisms remain unclear. In this study, we utilize a unique transgenic mouse model that mimics chronic non-bacterial prostatitis men investigate impact on androgen receptor (AR) basal stem cells (bPSC) their differentiation vivo. We find significantly enhances AR levels activity bPSC. More importantly, identify...
<p>PFS and OS by AJCC 8</p>
<p>B cell gating</p>
<p>Cytokines and Chemokines</p>
<p>Supplementary figure legends</p>
<p>Supplementary tables</p>
<p>Protocol</p>
<p>T cell gating</p>
<p>Cytokines and Chemokines</p>
<p>PFS and OS by AJCC 8</p>
<p>Supplementary tables</p>
<p>B cell gating</p>
<p>T cell gating</p>
<p>Supplementary figure legends</p>
<p>Protocol</p>
<div>AbstractPurpose:<p>Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), contraindication common. Radiation elicits promotes tumor-directed immune stimulation, which may potentiate anti–PD-1 therapy. We provide the first efficacy report combined pembrolizumab definitive in LA-HNSCC.</p>Patients Methods:<p>This single-arm, multi-institution, phase II study (NCT02609503) enrolled 29...
<div>AbstractPurpose:<p>Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), contraindication common. Radiation elicits promotes tumor-directed immune stimulation, which may potentiate anti–PD-1 therapy. We provide the first efficacy report combined pembrolizumab definitive in LA-HNSCC.</p>Patients Methods:<p>This single-arm, multi-institution, phase II study (NCT02609503) enrolled 29...
Abstract In the Phase II LCCC1520 trial, neoadjuvant chemo-immunotherapy (pembrolizumab with gemcitabine plus cisplatin) induced response in 22 of 39 muscle-invasive bladder cancer patients[1]. this correlative analysis, we identify molecular features associated and survival. Associations subtype, TMB, antigen presentation immune checkpoint gene expression survival were evaluated pre-and post-treatment. Neoantigens predicted 4 immuno-oncology data sets (LCCC1520, IMvigor210 cohorts 1[2]...